Nucleic acid, drug interactions

Bernard Pullman and Joshua Jortner, Molecular Basis of Specificity in Nucleic Acid-Drug Interactions. Proceedings of the 23rd Jerusalem Symposium on Quantum Chemistry and Biochemistry held in Jerusalem, Israel, May 14-17, 1990, in The Jerusalem Symposia on Quantum Chemistry and Biochemistry, Vol. 23, Kluwer, Dordrecht, 1990. 

The potential utility of N-labelcd oligonucleotides to probe unique nucleic acid structure, drug binding, and nucleic acid- protein interactions has led to considerable interest in the development of routes to the requisite N-labeled monomers. In the purine series, chemically synthesized N 1-labeled hypoxanthine was incorporated into a yeast tRNA by fermentation and... 

Figure 3 (a) Polyplexes are formed by electrostatic interaction between polycations and nucleic acids. Schematic interaction of positive polyplexes with the negatively charged cell membrane. Adapted from Pack, D. W. Hoffman, A. S. Pun, S. Stayton, P. S. Nat Rev. Drug Discov. 2005,4,581, copyright 2005 (b) Hypothetical scheme about the formation of covalent bonds between thiolated polymers and mucin glycoproteins. Adapted from Leitner, V. M. Walker, G. F. Bemkop-Schnurch, A. Eur. J. Pharm. Biopharm. 2003,56,207. ... 

Hawley, P. and Gibson, I., Interaction of oligodeoxynucleotides with mammalian cells. Antisense Nucleic Acid Drug Dev., 6,185,1996. 

Although the most widely used method to protect the nucleic acid drugs from possible external attack is electrostatic condensation with cationic polymers, encapsulation with neutral or hydrophobic polymers can also be used. In the latter case, the nucleic acid drugs are just physically trapped in a polymer matrix, and the main stabilization force of the polymer matrix is the passive hydrophobic interaction between the polymers in aqueous solution. Because there is no strong interaction between the polymer and the nucleic acid drugs, the encapsulation of nucleic acid drugs in the polymer matrix cannot be obtained by simple mixing, but only by more complicated fabrication methods. 

Chaires JB (2005) Structural Selectivity of Drug-Nucleic Acid Interactions Probed by Competition Dialysis. 253 33-53 Cherkinsky M, see Braverman S (2007) 275 67-101... 

Recent reviews in the field of platinum anticancer drugs focus on platinum-nucleobase chemistry [7], biological processing of platinum-modified DNA [8], trans-platinum anticancer drugs [5], cisplatin and derived anticancer drugs [4,9], proteins and cisplatin [10], trans-diam-mineplatinum(II) and nucleic acids [11], and catalytic activity and DNA [12], just to mention a few. The aim of this review is to explore the chemistry in the interaction of various platinum compounds with nucleic... 

Considerable progress has been made in understanding the chemical principles in Pt-nucleic acid interactions since the discovery of Pt antitumor drugs. At the same time, however, new questions have been raised upon development of novel drugs that violate the early structure-activity relationships. A common feature for various Pt drugs is that their initial binding to nucleic acid fragments seems to be controlled by the... 

---